GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

 Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines LONDON and WASHINGTON, Aug. 06, 2019 (GLOBE NEWSWIRE) — GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and […]

Read more